Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster
Corroborated by 1 source from 1 publisher
globalworld3h ago
TL;DR
According to seekingalpha.com, structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster Summary - Structure Therapeutics reported Phase 2 data for Aleniglipron, showing 16% weight loss at 44 weeks with strong tolerability and no safety signals.